<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The role of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha (TNF alpha) in brain injury is controversial </plain></SENT>
<SENT sid="1" pm="."><plain>We studied the effect of anti-TNF-alpha antibody in a rat model of reversible middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>During focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and early reperfusion, TNF-alpha was rapidly and transiently released into circulation </plain></SENT>
<SENT sid="3" pm="."><plain>Pretreatment with intravenous anti-TNF-alpha antibody reduced cortical (71%, P &lt; 0.015) and subcortical (58%, P &lt; 0.007) injury, enhanced the cerebral blood flow during reperfusion, and improved the neurologic outcome </plain></SENT>
<SENT sid="4" pm="."><plain>This further supports the contention that TNF-alpha is a deleterious cytokine in <z:hpo ids='HP_0001297'>stroke</z:hpo>, whereas circulating antibody against TNF-alpha may protect brain from reperfusion injury </plain></SENT>
</text></document>